# Nimotuzumab in Adults With Pancreatic Cancer

> **NCT00561990** · PHASE2,PHASE3 · COMPLETED · sponsor: **Oncoscience AG** · enrollment: 188 (estimated)

## Conditions studied

- Pancreatic Cancer, Advanced or Metastatic

## Interventions

- **DRUG:** Nimotuzumab

## Key facts

- **NCT ID:** NCT00561990
- **Lead sponsor:** Oncoscience AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2013-01
- **Final completion:** 2014-01
- **Target enrollment:** 188 (ESTIMATED)
- **Last updated:** 2015-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00561990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00561990, "Nimotuzumab in Adults With Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00561990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*